{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"description":"Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 2.\n\nDescription of Grades:\n\nGrade 1: Mild Grade 2: Moderate Grade 3: Severe Grade 4: Life-threatening Grade 5: Death","groups":[{"description":"Thalidomide (Thal) + Zolendronic acid (ZLD)","id":"OG000","title":"Arm I: Thal/ZLD"},{"description":"Zoledronic acid (ZLD)","id":"OG001","title":"Arm II: ZLD"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"During treatment (up to 5 years)","title":"Number of Participants With Severe (Grade 3, 4 or 5) Adverse Events","type":"SECONDARY","unitOfMeasure":"participants"}